Paul Rennie Purchases 5,181,688 Shares of Paradigm Biopharmaceuticals Limited (ASX:PAR) Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Paul Rennie purchased 5,181,688 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were purchased at an average price of A$0.50 ($0.32) per share, for a total transaction of A$2,590,844.00 ($1,650,219.11).

Paradigm Biopharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.93 and a current ratio of 7.22. The firm has a market capitalization of $196.66 million, a PE ratio of -2.47 and a beta of 0.94.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.